<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03091127</url>
  </required_header>
  <id_info>
    <org_study_id>20150262</org_study_id>
    <nct_id>NCT03091127</nct_id>
  </id_info>
  <brief_title>Real-world Use of Carfilzomib Among Multiple Myeloma Patients in Europe</brief_title>
  <official_title>Real-world Use of Carfilzomib Among Multiple Myeloma Patients in Europe Who Have Received at Least One Prior Therapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      With the recent addition of carfilzomib as a treatment option for multiple myeloma, no data
      is available yet on how the drug is being used outside of the clinical trial setting.

      This study will therefore provide essential data to demonstrate the real world utilization of
      carfilzomib in routine clinical practice, including dosage, administration schedule, regimen,
      duration of treatment and reason for discontinuation in Europe.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      With the recent addition of carfilzomib as a treatment option for multiple myeloma, no data
      is available yet on how the drug is being used outside of the clinical trial setting.

      The Primary Objective is to describe carfilzomib utilisation in routine clinical practice,
      including dosage, administration schedule, regimen, duration of treatment and reason for
      discontinuation.

      âˆ’ Secondary Objectives:

        -  Describe the population treated with carfilzomib in terms of demographics, multiple
           myeloma (MM) disease characteristics, treatment history, and comorbidities.

        -  Describe the safety profile of carfilzomib in routine clinical practice.

        -  Describe response to treatment as assessed by the physician and recorded in the medical
           file.

        -  Describe healthcare resource utilisation of subjects treated with carfilzomib, in terms
           of unplanned hospitalisations.

        -  Describe the reasons for choosing carfilzomib as the MM treatment of choice.

        -  Describe specific concomitant therapy (bisphosphonates, thromboprophylaxis,
           antihypertensive treatment, anti-infective treatment) and whether these therapies were
           used as prophylaxis or as treatment.

        -  Describe a cardiovascular assessment at carfilzomib regimen initiation and at occurrence
           of cardiac adverse events, where available per routine care (electrocardiogram [ECG],
           echocardiography, left ventricular ejection fraction).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 14, 2017</start_date>
  <completion_date type="Actual">March 17, 2020</completion_date>
  <primary_completion_date type="Actual">March 17, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Carfilzomib starting dose</measure>
    <time_frame>18 months</time_frame>
    <description>Carfilzomib dose at first administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Carfilzomib dose</measure>
    <time_frame>18 months</time_frame>
    <description>Carfilzomib dose at subsequent administrations</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Carfilzomib dose modification</measure>
    <time_frame>18 months</time_frame>
    <description>Modification includes change in dose level, dose interruption, and dose delays</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to carfilzomib dose modification</measure>
    <time_frame>18 months</time_frame>
    <description>At least one carfilzomib dose modification, escalation or reduction</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reason for dose modification</measure>
    <time_frame>18 months</time_frame>
    <description>Reason for dose modification or delay</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of cycles started</measure>
    <time_frame>18 months</time_frame>
    <description>Number of carfilzomib treatment cycles started throughout study period</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Carfilzomib regimen</measure>
    <time_frame>18 months</time_frame>
    <description>Treatment combination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Carfilzomib dosing frequency</measure>
    <time_frame>18 months</time_frame>
    <description>Number of administrations per cycle</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Carfilzomib dosing schedule</measure>
    <time_frame>18 months</time_frame>
    <description>Timing of carfilzomib administration within treatment cycle</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Carfilzomib duration of treatment</measure>
    <time_frame>18 months</time_frame>
    <description>Duration of carfilzomib treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Starting dose of concomitant anti-myeloma agents</measure>
    <time_frame>18 months</time_frame>
    <description>Dose of combination agents (e.g. lenalidomide or dexamethasone) at baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose modification for concomitant anti-myeloma agents</measure>
    <time_frame>18 months</time_frame>
    <description>Modification includes change in dose level, dose interruption, and dose delays</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reason for frequency modification</measure>
    <time_frame>18 months</time_frame>
    <description>At least 1 change in frequency of carfilzomib administration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reason for change in frequency of concomitant multiple myeloma therapies</measure>
    <time_frame>18 months</time_frame>
    <description>Reason for change in frequency of administration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>International Staging System (ISS) score and revised ISS stage at diagnosis and carfilzomib regimen initation</measure>
    <time_frame>18 months</time_frame>
    <description>International Staging System (ISS) score of I, II, III, or unkown</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eastern Cooperative Oncology Group (ECOG) performance status</measure>
    <time_frame>18 months</time_frame>
    <description>ECOG performance status category at multiple myeloma diagnosis and carfilzomib regimen initiation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytogenetic risk profile at diagnosis</measure>
    <time_frame>18 months</time_frame>
    <description>Cytogenetic risk profile at diagnosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of CRAB features (i.e. hypercalcemia, renal insufficiency, anemia and/or bone pain)</measure>
    <time_frame>18 months</time_frame>
    <description>Presence of CRAB features at MM diagnosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of comorbidities</measure>
    <time_frame>18 months</time_frame>
    <description>Diagnosed at any point in time before carflzomib regimen initiation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Previously received anti-myeloma treatment</measure>
    <time_frame>18 months</time_frame>
    <description>Treatment history</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response to prior treatment</measure>
    <time_frame>18 months</time_frame>
    <description>Response to prior treatment received before initiation of carfilzomib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of prior relapses</measure>
    <time_frame>18 months</time_frame>
    <description>Type of relapse (molecular, hematologic, or symptomatic)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event</measure>
    <time_frame>18 months</time_frame>
    <description>All grade 3 or above adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to adverse event</measure>
    <time_frame>18 months</time_frame>
    <description>All grade 3 or above adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrocardiogram (ECG) changes</measure>
    <time_frame>18 months</time_frame>
    <description>ECG changes as recorded in tests performed per routine practice</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease in left ventricular ejection fraction (LVEF)</measure>
    <time_frame>18 months</time_frame>
    <description>LVEF decrease as recorded in tests performed per routine practice</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Initiation or dose increase of antihypertensive treatment</measure>
    <time_frame>18 months</time_frame>
    <description>Initiation or dose increase of existing antihypertensive treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Initiation or dose increase of existing heart failure treatment</measure>
    <time_frame>18 months</time_frame>
    <description>Initiation or dose increase of existing heart failure treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response to carfilzomib treatment</measure>
    <time_frame>18 months</time_frame>
    <description>Physician-assessed response as recorded on the medical charts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type of relapse</measure>
    <time_frame>18 months</time_frame>
    <description>Molecular, hematologic or symptomatic relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of unplanned hospitalisations</measure>
    <time_frame>18 months</time_frame>
    <description>Initiation or dose increase of existing heart failure treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concomitant therapy not part of the carfilzomib regimen</measure>
    <time_frame>18 months</time_frame>
    <description>Concomitant therapy not part of the carfilzomib regimen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Planned subsequent treatment regimen</measure>
    <time_frame>18 months</time_frame>
    <description>Planned subsequent treatment regimen catergory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient age</measure>
    <time_frame>18 months</time_frame>
    <description>Patient age</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient sex</measure>
    <time_frame>18 months</time_frame>
    <description>Patient sex</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient height</measure>
    <time_frame>18 months</time_frame>
    <description>Patient height</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient weight</measure>
    <time_frame>18 months</time_frame>
    <description>Patient weight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRI (magnetic resonance imaging) performed at MM diagnosis and carfilzomib regimen initiation.</measure>
    <time_frame>18 months</time_frame>
    <description>MRI (magnetic resonance imaging)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PET-CT (positron emission tomography-computed tomography) performed at MM diagnosis and carfilzomib regimen initiation.</measure>
    <time_frame>18 months</time_frame>
    <description>PET-CT (positron emission tomography-computed tomography)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of Serum M component at MM diagnosis and carfilzomib regimen initiation.</measure>
    <time_frame>18 months</time_frame>
    <description>Serum M component</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of Urine M component at MM diagnosis and carfilzomib regimen initiation.</measure>
    <time_frame>18 months</time_frame>
    <description>Urine M component</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of serum albumin at MM diagnosis and carfilzomib regimen initiation.</measure>
    <time_frame>18 months</time_frame>
    <description>Serum albumin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of serum beta-2-microglobulin at MM diagnosis and carfilzomib regimen initiation.</measure>
    <time_frame>18 months</time_frame>
    <description>Beta-2-microglobulin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of percent of plasma cells in bone marrow at MM diagnosis and carfilzomib regimen initiation.</measure>
    <time_frame>18 months</time_frame>
    <description>Percent of plasma cells in bone marrow</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline measurement of lactate dehydrogenase at MM diagnosis and carfilzomib regimen initiation.</measure>
    <time_frame>18 months</time_frame>
    <description>Lactate dehydrogenase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECG (electrocardiogram)</measure>
    <time_frame>18 months</time_frame>
    <description>ECG (electrocardiogram)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiogram</measure>
    <time_frame>18 months</time_frame>
    <description>Echocardiogram</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LVEF (left ventricular ejection fraction) assessment</measure>
    <time_frame>18 months</time_frame>
    <description>LVEF (left ventricular ejection fraction) assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Computed Tomography (CT) performed at MM diagnosis and carfilzomib regiment initiation.</measure>
    <time_frame>18 Months</time_frame>
    <description>Computed tomography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myeloma/Osteolytic lesions detected by MRI, PET-CT, and X-ray at MM diagnosis and carfilzomib regimen initiation</measure>
    <time_frame>18 months</time_frame>
    <description>Myeloma/Osteolytic lesions detected by MRI, PET-CT, and X-ray at MM diagnosis and carfilzomib regimen initiation</description>
  </secondary_outcome>
  <enrollment type="Actual">705</enrollment>
  <condition>Multiple Myeloma</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Multiple Myeloma
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years or older at the time of carfilzomib initiation

          -  At least one prior line of MM treatment has been received

          -  Carfilzomib treatment has been initiated per routine practice and is currently ongoing

          -  At least one administration of carfilzomib in a combination regimen (ie, not
             monotherapy) has been received

          -  Provided written informed consent prior to abstraction of any data, in countries where
             written informed consent is required.

          -  Subjects who previously completed treatment with carfilzomib in a clinical trial, a
             compassionate use program or through routine practice, are eligible to take part in
             the study.

          -  Subjects who receive radiotherapy concurrently with carfilzomib treatment are also
             eligible to take part in the study.

          -  Subjects who initiate carfilzomib treatment on a combination regimen, subsequently
             discontinue all concomitant medications but remain on carfilzomib monotherapy in later
             cycles, remain eligible for participation in the study.

          -  Subjects who are also enrolled in other observational studies in which standard of
             care is not altered are eligible to take part in the study,

        Exclusion Criteria:

          -  Subjects who are enrolled in a carfilzomib clinical trial will not be eligible to
             additionally take part in this observational study.

          -  Subjects who are receiving carfilzomib treatment within a compassionate use program
             will not be eligible to take part in this observational study. If a subject who has
             enrolled into this observational study, also enrolls in a clinical trial in which MM
             treatment and/or disease management is protocol-specified, the subject becomes
             ineligible and the subject's data will be censored from the time the subject enrolled
             the clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Braunau</city>
        <zip>5280</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leoben</city>
        <zip>8700</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Linz</city>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rankweil</city>
        <zip>6830</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Schwarzach im Pongau</city>
        <zip>5620</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Steyr</city>
        <zip>4400</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Waidhofen an der Ybbs</city>
        <zip>3340</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wels</city>
        <zip>4600</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wiener Neustadt</city>
        <zip>2700</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bonheiden</city>
        <zip>2820</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brussels</city>
        <zip>1160</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Geel</city>
        <zip>2440</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Haine Saint Paul - La Louviere</city>
        <zip>7100</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ieper</city>
        <zip>8900</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sint-Niklaas</city>
        <zip>9100</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tournai</city>
        <zip>7500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Verviers</city>
        <zip>4800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sofia</city>
        <zip>1606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sofia</city>
        <zip>1756</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>500 05</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Olomouc</city>
        <zip>775 20</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Plzen</city>
        <zip>304 60</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Praha 2</city>
        <zip>128 08</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Avignon Cedex 9</city>
        <zip>84902</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bayonne</city>
        <zip>64109</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Grenoble Cedex 9</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Limoges Cedex</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montpellier cedex 5</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nimes cedex 09</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Poitiers Cedex</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pontoise Cedex</city>
        <zip>95301</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Reims cedex</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Quentin</city>
        <zip>02321</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Alexandroupoli</city>
        <zip>68100</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Athens</city>
        <zip>10676</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Athens</city>
        <zip>11526</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Athens</city>
        <zip>11528</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Athens</city>
        <zip>12462</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Athens</city>
        <zip>15562</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Athens</city>
        <zip>18547</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Heraklion</city>
        <zip>71110</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Larissa</city>
        <zip>41110</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Patra</city>
        <zip>26335</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Patra</city>
        <zip>26500</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Piraeus</city>
        <zip>18537</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54007</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Thessaloniki</city>
        <zip>57010</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Petah Tiqva</city>
        <zip>4941492</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tel Aviv</city>
        <zip>6423906</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Alessandria</city>
        <zip>15121</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bagno A Ripoli (FI)</city>
        <zip>50012</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barletta</city>
        <zip>76121</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Benevento</city>
        <zip>82100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bergamo</city>
        <zip>24127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brindisi</city>
        <zip>72100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cagliari</city>
        <zip>09121</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cuneo</city>
        <zip>12100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lecco</city>
        <zip>23900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Livorno</city>
        <zip>57123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Messina</city>
        <zip>98158</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Milano</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pagani (SA)</city>
        <zip>84016</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Palermo</city>
        <zip>90146</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Perugia</city>
        <zip>06156</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pescara</city>
        <zip>65124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Potenza</city>
        <zip>85100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Reggio Calabria</city>
        <zip>89124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Reggio Emilia</city>
        <zip>42100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Roma</city>
        <zip>00133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Roma</city>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Roma</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Roma</city>
        <zip>00189</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Salerno</city>
        <zip>84131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taranto</city>
        <zip>74123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Udine</city>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Verona</city>
        <zip>37134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Beverwijk</city>
        <zip>1942 LE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Breda</city>
        <zip>4819 EV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Den Haag</city>
        <zip>2545 CH</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nieuwegein</city>
        <zip>3435 CM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Schiedam</city>
        <zip>3118 JH</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Venlo</city>
        <zip>5912 BL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bergen</city>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oslo</city>
        <zip>0372</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Baia Mare</city>
        <zip>430031</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brasov</city>
        <zip>500152</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bucharest</city>
        <zip>020125</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bucharest</city>
        <zip>022328</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bucharest</city>
        <zip>030171</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bucuresti</city>
        <zip>010825</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bucuresti</city>
        <zip>022328</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cluj-Napoca</city>
        <zip>400124</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Craiova</city>
        <zip>200143</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Iasi</city>
        <zip>700483</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oradea</city>
        <zip>410469</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Targu Mures</city>
        <zip>540136</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Timisoara</city>
        <zip>300239</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Greece</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Romania</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>January 30, 2017</study_first_submitted>
  <study_first_submitted_qc>March 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2017</study_first_posted>
  <last_update_submitted>March 23, 2020</last_update_submitted>
  <last_update_submitted_qc>March 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.</ipd_time_frame>
    <ipd_access_criteria>Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the link below.</ipd_access_criteria>
    <ipd_url>https://www.amgen.com/datasharing</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

